Orexigen Therapeutics, Inc. (NASDAQ:OREX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar pchop12316 (86.37) Submitted: 9/15/2014 4:41:07 PM : Underperform Start Price: $4.85 OREX Score: +2.70

upside in price not on near horizon

Recs

0
Member Avatar genedom (97.66) Submitted: 6/22/2014 12:37:48 PM : Outperform Start Price: $6.07 OREX Score: -23.83

Undervalued stock with huge momentum.

Recs

0
Member Avatar TerryFool (< 20) Submitted: 4/4/2014 3:50:32 PM : Outperform Start Price: $5.78 OREX Score: -25.05

BUY PULLBACK

Recs

0
Member Avatar TMFBiologyFool (96.18) Submitted: 1/28/2014 11:30:26 AM : Outperform Start Price: $6.80 OREX Score: -42.22

Takeda appears willing to do what it takes to make Contrave successful.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:48:21 PM : Underperform Start Price: $6.96 OREX Score: +51.97

Short. Trading at 200x sales. Massive losses and selling tons of stock.

Recs

0
Member Avatar solanZRaider (< 20) Submitted: 3/4/2013 4:19:11 PM : Outperform Start Price: $6.55 OREX Score: -57.79

HealthcareGuy

Recs

0
Member Avatar adamlevy (84.36) Submitted: 1/17/2013 3:17:22 PM : Outperform Start Price: $6.30 OREX Score: -59.77

Despite coming to the market later than the competition, I believe Orexigen has the best chance to become the market leader in the newly rejuvenated obesity drug market.

The company's drug, Contrave, is not considered a controlled substance unlike the competition. Doctors are more likely to prescribe a drug that is less habit forming and easier to get a refill of.

Additionally, the company expects great results form the cardiovascular safety study required for FDA approval. They expect results in the second quarter of this year, ahead of schedule, allowing them to get the drug to market as early as the first quarter of 2014.

They also have the benefit of Takeda Pharmaceuticals, which will likely commit more sales reps to Contrave than Arena and Vivus have for their drugs combined.

Recs

0
Member Avatar starpark88 (86.68) Submitted: 1/7/2013 9:46:43 AM : Outperform Start Price: $6.04 OREX Score: -58.81

Contrave makes the most sense out of the other anti obesity drugs in the pipeline.

Qsynia is out in my opinion as the risk of birth defects rules out a huge market of potential customers.

Belviq seems alright and I like what they're doing in focusing on diabetes, but imo doesn't lead to enough average weight loss for rational insurers to cover the hefty cost.

Beloranib is interesting but what percentage of the market can it get when the drug is IV? I

Contrave seems to hit that sweet spot of decent average weight loss without major average side effects. We'll see what happens with the FDA but if I was forced to choose one of these four medications to succeed, Contrave would have my vote.

Recs

0
Member Avatar 78taxs (< 20) Submitted: 8/4/2012 5:53:36 PM : Outperform Start Price: $4.61 OREX Score: -40.31

there doing well

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 6/27/2012 8:46:53 PM : Outperform Start Price: $5.53 OREX Score: -65.46

porto. likedded it.

Recs

0
Member Avatar Flipdaflop (< 20) Submitted: 6/8/2012 4:17:24 PM : Outperform Start Price: $3.42 OREX Score: -10.11

Give it a shoot what do you have to loose money lol let get it

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 2/2/2012 8:46:37 PM : Underperform Start Price: $2.73 OREX Score: -23.24

So far, 2012 has been the year of baby biotech. Right now, anyone who made a New Year's resolution to invest in the sector is thinking they're a genius. But those of us who have been around long enough to see the tide roll in and out a few times are making our preparations for the lean times that will surely follow. I've been selling my more speculative positions into strength, and in the case of Orexigen it seems I left a few thousand dollars on the table.

Just a few short months ago I decried the irrationality of Orexigen traders as the share price meandered completely unfettered to the fundamental catalysts that determined the future of the company. In September the share price was as low as 1.28, giving the company a market cap well below their cash reserves. Since then, the only positive development has been a communication from the FDA that they would accept an interim analysis of the proposed cardiovascular outcomes study as sufficient grounds for approval of Contrave. The share price spiked as high as 2.6, then declined as low as 1.51 again before embarking on the most recent upward trajectory.

The market cap is now 132M and the cash position will almost certainly be below 60M the next time earnings are reported. But the outcomes study hasn't even started yet and the company estimates that it will be at least two years before the interim analysis can be performed. And of course the whole situation still suggests that the FDA sent Orexigen off on a virtually impossible task in order to avoid ever being asked to approve Contrave again. I gobbled this stock over the summer when the price was 1.5, but now I wouldn't buy a share over 1.3.

Recs

1
Member Avatar siri22 (< 20) Submitted: 12/16/2011 3:16:43 PM : Outperform Start Price: $1.58 OREX Score: +136.85

A two year wait for an gaurnteed 10 bagger, damn smartphone

Recs

0
Member Avatar Lcrazylegs84 (< 20) Submitted: 9/21/2011 9:02:03 PM : Outperform Start Price: $2.13 OREX Score: +46.73

Its ready to make me some money!!!

Recs

0
Member Avatar modestus1 (< 20) Submitted: 6/3/2011 12:52:58 AM : Outperform Start Price: $2.14 OREX Score: +68.69

Friday's announcement

Recs

0
Member Avatar jsgant13 (99.03) Submitted: 2/8/2011 9:39:51 PM : Outperform Start Price: $3.50 OREX Score: -15.52

sac

Recs

1
Member Avatar telcomac99 (79.57) Submitted: 2/7/2011 9:41:09 AM : Outperform Start Price: $3.99 OREX Score: -32.74

The drug still has a chance... after big drop last week, seems like the risk/reward ratio is very favorable, especially for the CAPS portfolio. Let's see if I can't pick up a quick couple points on the rebound and lock in a winner...

Recs

0
Member Avatar yik6402 (< 20) Submitted: 1/15/2011 11:44:34 PM : Outperform Start Price: $9.55 OREX Score: -105.42

I believe this "contrave" will be extremely critical coming Jan 31 when FDA approves or disapprove. The Board of Review already voted 13-7 most of the time the FDA approves on the recommendations. The other two Arena and VVUS pose no threat here but VVUS already gone over seas to seek aprroval but if Contrave Approves most likely they will try to go ove to Europe to Broaden sales and groth to the company. All in all its in the Bag!

Recs

0
Member Avatar albiedog (< 20) Submitted: 12/24/2010 4:55:43 PM : Outperform Start Price: $8.00 OREX Score: -100.77

Just got recomendation for approval from FDA advisory committee. Expected to get FDA approval in Jan.

Recs

0
Member Avatar chakkar1 (< 20) Submitted: 12/14/2010 9:45:08 AM : Outperform Start Price: $8.88 OREX Score: -107.22

Strong possibility of Contrave being approved by the FDA (31-Jan-2011 meeting) after early Dec-2010 recommendation from FDA advisory panel. Contrave is made up of two FDA-approved drugs with long histories and data to back up safety claims.

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement